Injective (INJ) is currently priced at $2.96, reflecting a 7.75% increase over the last 24 hours. The price has reached a daily high of $2.96, indicating strong bullish momentum, while the low for the same period stands at $2.75, showcasing a relatively tight daily range of 0.21%.

The trading volume of 39,313,116 signifies active participation, with a volume-to-market cap ratio of 13.29%. This suggests that the market is sufficiently liquid, potentially supporting further price movements as investors engage with INJ.

The hourly moving averages present a bullish trend, with the 8 SMA at $2.90 showing a 2.17% increase, and the longer-term averages also reflecting positive momentum. Notably, the 21 SMA at $2.84 has increased by 4.23%, indicating that short to medium-term trends are favorable for price appreciation.

The 1-hour Relative Strength Index (RSI) is at an exceptionally high level of 90, suggesting that INJ may be overbought in the very short term. However, the 7-day RSI at 53 indicates a more balanced market condition, allowing room for growth without the immediate risk of a pullback.

Over the past week, INJ has seen a price change of approximately 1.27%, while the 14-day change is negative at -2.63%. This indicates a recent recovery in sentiment after a dip, with the 30-day price change being positive at 2.45%, suggesting a longer-term upward trend.

Considering the all-time high of $52.62 achieved earlier this year, there is significant potential for price recovery and growth. The current market dynamics and technical indicators point towards a favorable trading environment for INJ, although caution is warranted due to the high 1-hour RSI.

In conclusion, the current price action and technical indicators suggest a bullish sentiment for Injective (INJ). Therefore, the rating is a Buy, driven by strong recent performance, positive moving averages, and a supportive volume trend. However, short-term traders should monitor the high RSI closely for potential corrections.